

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 C07D513/04 A61K31/41

A61P25/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 1 464 259 A (PFIZER LTD) 9 February 1977 (1977-02-09) claim 1	26-36
A		1-25, 37-39
X	ANDANAPPA K ET AL: "Synthesis and biological evaluation of 6-aryl-N-‘(dimethylamino)methylene 5-formylimidazo‘2,1-b!-1,3,4-thiadiazole-2-sulfonamides as antitumor agents" ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, EDITIO CANTOR. AULENDORF, DE, vol. 49, no. 10, 1999, pages 858-863, XP002232876 ISSN: 0004-4172 cited in the application Tables 1 and 2	26-36
A		1-25, 37-39
		-/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

4 November 2004

Date of mailing of the international search report

11/11/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patenlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Wolf, C

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>TALLEY J J ET AL: "N-'(5-Methyl-3-phenylisoxazol-4-yl)-phenylsulfonyl!propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor COX-2 for parenteral administration" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, no. 9, 4 May 2000 (2000-05-04), pages 1661-1663, XP002208175 ISSN: 0022-2623 cited in the application Scheme 1</p> <p>-----</p>	1-39
P, X	<p>WO 03/051890 A (AEGERA THERAPEUTICS INC ; VILLENEUVE GERALD (CA); DURKIN JON (CA); GIL) 26 June 2003 (2003-06-26) cited in the application</p> <p>-----</p>	26-36
A, P	<p>Claim 1</p> <p>-----</p>	1-25, 37-39

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2004/000873

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 17-25, 29-36, 38, 39
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 17-25, 29-36, 38, 39 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
GB 1464259	A	09-02-1977	NONE		
WO 03051890	A	26-06-2003	CA	2364985 A1	14-06-2003
			WO	03051890 A1	26-06-2003
			CA	2469953 A1	26-06-2003
			EP	1463735 A1	06-10-2004

BEST AVAILABLE COPY